Table 6.
Management of ICPI-induced uveitis.
| Anterior Uveitis, n (%) |
Intermediate Uveitis, n (%) |
Posterior Uveitis, n (%) |
Panuveitis, n (%) |
Total of Uveitis, n (%) |
|
|---|---|---|---|---|---|
| ICPI management | |||||
| - Permanent discontinuation | 5 (45) | 2 (50) | 1 (33) | 5 (71) | 13 (52) |
| - Continuation | 2 (18) | 1 (25) | 1 (33) | 2 (28) | 6 (24) |
| - Monotherapy 1 | 3 (27) | - | - | - | 3 (12) |
| - Unknown status | 1 (9) | 1 (25) | 1 (33) | - | 3 (12) |
| Topical and systemic steroids | 3 (27) | - | 1 (33) | 6 (86) | 10 (40) |
| Topical steroids only | 7 (64) | 3 (75) | 1 (33) | 1 (14) | 12 (48) |
| Systemic steroids only | - | - | 1 (33) | - | 1 (4) |
| None | 1 (9) | 1 (25) | - | - | 2 (8) |
1 Nivolumab monotherapy instead of ipilimumab/nivolumab combination therapy.